目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 48)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.3.2 REGIONS COVERED
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
1.5.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY (Page No. - 53)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 1 LIQUID BIOPSY MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
FIGURE 5 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 6 LIQUID BIOPSY INDUSTRY: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 STUDY ASSUMPTIONS
2.6 GROWTH RATE ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.8 RISK ASSESSMENT
2.9 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY (Page No. - 66)
FIGURE 8 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION)
FIGURE 9 LIQUID BIOPSY INDUSTRY, BY CIRCULATING BIOMARKER, 2024 VS. 2029 (USD MILLION)
FIGURE 10 MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
FIGURE 11 MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 12 MARKET, BY CLINICAL APPLICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 13 MARKET, BY SAMPLE TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 14 MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 15 MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 72)
4.1 LIQUID BIOPSY MARKET OVERVIEW
FIGURE 16 INCREASING DEMAND FOR MINIMALLY INVASIVE DIAGNOSTIC TECHNIQUES TO SUPPORT MARKET GROWTH DURING FORECAST PERIOD
4.2 LIQUID BIOPSY INDUSTRY, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION)
FIGURE 17 ASSAY KITS SEGMENT TO DOMINATE MARKET THROUGHOUT FORECAST PERIOD
4.3 MARKET, BY CIRCULATING BIOMARKER, 2024 VS. 2029 (USD MILLION)
FIGURE 18 CIRCULATING TUMOR CELLS SEGMENT TO HOLD LARGEST MARKET SHARE TILL 2029
4.4 MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
FIGURE 19 MULTI-GENE PARALLEL ANALYSIS USING NGS SEGMENT TO ACCOUNT FOR LARGEST SHARE OF TECHNOLOGY MARKET
4.5 MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 20 CANCER APPLICATIONS SEGMENT TO RETAIN MARKET DOMINANCE TILL 2029
4.6 MARKET, BY CLINICAL APPLICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 21 THERAPY SELECTION AND TREATMENT MONITORING TO HOLD LARGEST MARKET SHARES THROUGHOUT FORECAST PERIOD
4.7 MARKET, BY SAMPLE TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 22 BLOOD SAMPLES TO DOMINATE MARKET TILL 2029
4.8 MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 23 REFERENCE LABORATORIES TO ACCOUNT FOR LARGEST SHARE
4.9 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 24 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 77)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 25 LIQUID BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence and prevalence of cancer
TABLE 1 INCIDENCE OF CANCER CASES WORLDWIDE, BY TYPE (2022)
TABLE 2 PROJECTED INCREASE IN CANCER PATIENTS, BY REGION (2022 VS 2035 VS 2045)
5.2.1.2 Cancer awareness initiatives undertaken by global health organizations
5.2.1.3 Benefits of liquid biopsy over traditional biopsy procedures
5.2.2 RESTRAINTS
5.2.2.1 Lower sensitivity of certain liquid biopsy procedures
5.2.3 OPPORTUNITIES
5.2.3.1 Growing significance of companion diagnostics
5.2.3.2 Growth opportunities in emerging countries
5.2.4 CHALLENGES
5.2.4.1 Unclear reimbursement scenario
5.3 PRICING ANALYSIS
TABLE 3 INDICATIVE PRICING OF KEY PLAYERS, BY PRODUCT
5.4 PATENT ANALYSIS
FIGURE 26 PATENT ANALYSIS FOR LIQUID BIOPSY (JANUARY 2014-DECEMBER 2023)
5.4.1 LIST OF MAJOR PATENTS
5.5 VALUE CHAIN ANALYSIS
FIGURE 27 VALUE CHAIN ANALYSIS OF LIQUID BIOPSY INDUSTRY: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 28 MARKET: SUPPLY CHAIN ANALYSIS
5.7 TRADE ANALYSIS
5.7.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
TABLE 6 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)
TABLE 7 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)
5.8 ECOSYSTEM ANALYSIS
FIGURE 29 MARKET: ECOSYSTEM ANALYSIS
5.8.1 MARKET PLAYERS: ROLE IN ECOSYSTEM
5.9 PORTER’S FIVE FORCES ANALYSIS
5.9.1 THREAT OF NEW ENTRANTS
5.9.2 THREAT OF SUBSTITUTES
5.9.3 BARGAINING POWER OF BUYERS
5.9.4 BARGAINING POWER OF SUPPLIERS
5.9.5 INTENSITY OF COMPETITIVE RIVALRY
5.10 KEY STAKEHOLDERS & BUYING CRITERIA
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LIQUID BIOPSY PRODUCTS
TABLE 9 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LIQUID BIOPSY PRODUCTS (%)
5.10.2 BUYING CRITERIA
FIGURE 31 KEY BUYING CRITERIA FOR LIQUID BIOPSY PRODUCTS
TABLE 10 KEY BUYING CRITERIA FOR LIQUID BIOPSY PRODUCTS
5.11 REGULATORY LANDSCAPE
5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11.2 NORTH AMERICA
5.11.2.1 US
5.11.2.2 Canada
5.11.3 EUROPE
TABLE 16 EUROPE: CLASSIFICATION OF DEVICES
5.11.4 ASIA PACIFIC
5.11.4.1 China
5.11.4.2 Japan
TABLE 17 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.11.4.3 India
5.11.5 LATIN AMERICA
5.11.5.1 Brazil
5.11.5.2 Mexico
5.11.6 MIDDLE EAST
5.11.6.1 Africa
5.12 TECHNOLOGY ANALYSIS
5.12.1 KEY TECHNOLOGIES
5.12.1.1 Digital Droplet PCR
5.12.1.2 Tagged-Amplicon Deep Sequencing
5.12.2 COMPLEMENTARY TECHNOLOGIES
5.12.2.1 Electrochemical biosensing technology
5.12.3 ADJACENT TECHNOLOGIES
5.12.3.1 Microfluidics-based Devices
5.13 KEY CONFERENCES & EVENTS IN 2024-2025
TABLE 18 MARKET: DETAILED LIST OF CONFERENCES & EVENTS
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 32 REVENUE SHIFT IN MARKET
5.15 INVESTMENT & FUNDING SCENARIO
FIGURE 33 MARKET: INVESTMENT & FUNDING SCENARIO
5.16 CASE STUDY ANALYSIS
5.16.1 CASE STUDY 1: ANALYTICAL VALIDATION OF TARGET SELECTOR CTDNA PLATFORM
5.16.2 CASE STUDY 2: DETERMINING OPTIMAL MUTATION DETECTION MEDIUM

6 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE (Page No. - 102)
6.1 INTRODUCTION
TABLE 19 LIQUID BIOPSY INDUSTRY, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
6.1.1 PRIMARY NOTES
6.1.1.1 Key Industry Insights
6.2 ASSAY KITS
6.2.1 RECURRENT REQUIREMENTS AND PURCHASES OF ASSAY KITS TO DRIVE GROWTH
TABLE 20 KEY PRODUCTS IN ASSAY KITS MARKET
TABLE 21 LIQUID BIOPSY ASSAY KITS MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 22 NORTH AMERICA: LIQUID BIOPSY ASSAY KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 23 EUROPE: LIQUID BIOPSY ASSAY KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 24 ASIA PACIFIC: LIQUID BIOPSY ASSAY KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 25 LATIN AMERICA: LIQUID BIOPSY ASSAY KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 INCREASING NEED FOR FASTER & MORE ACCURATE TEST RESULTS TO ENSURE MARKET GROWTH
TABLE 26 KEY PRODUCTS IN INSTRUMENTS MARKET
TABLE 27 LIQUID BIOPSY INSTRUMENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 28 NORTH AMERICA: LIQUID BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 29 EUROPE: LIQUID BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 30 ASIA PACIFIC: LIQUID BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 31 LATIN AMERICA: LIQUID BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
6.4 SERVICES
6.4.1 INCREASING NUMBER OF LIQUID BIOPSY-BASED SERVICE DEVELOPMENTS TO SUPPORT MARKET GROWTH
TABLE 32 LIQUID BIOPSY SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 33 NORTH AMERICA: LIQUID BIOPSY SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 34 EUROPE: LIQUID BIOPSY SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 35 ASIA PACIFIC: LIQUID BIOPSY SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 36 LATIN AMERICA: LIQUID BIOPSY SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)

7 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER (Page No. - 113)
7.1 INTRODUCTION
TABLE 37 LIQUID BIOPSY INDUSTRY, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
7.2 CIRCULATING TUMOR CELLS
7.2.1 EASY COLLECTION AND PERSISTENT ASSESSMENT & ANALYSIS OF TUMOR BURDEN TO DRIVE DEMAND
TABLE 38 MARKET FOR CIRCULATING TUMOR CELLS, BY REGION, 2022-2029 (USD MILLION)
TABLE 39 NORTH AMERICA: MARKET FOR CIRCULATING TUMOR CELLS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 40 EUROPE: MARKET FOR CIRCULATING TUMOR CELLS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 41 ASIA PACIFIC: MARKET FOR CIRCULATING TUMOR CELLS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 42 LATIN AMERICA: MARKET FOR CIRCULATING TUMOR CELLS, BY COUNTRY, 2022-2029 (USD MILLION)
7.3 CIRCULATING TUMOR DNA
7.3.1 HIGH SENSITIVITY AND SPECIFICITY TO FAVOR ADOPTION
TABLE 43 MARKET FOR CIRCULATING TUMOR DNA, BY REGION, 2022-2029 (USD MILLION)
TABLE 44 NORTH AMERICA: MARKET FOR CIRCULATING TUMOR DNA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 45 EUROPE: MARKET FOR CIRCULATING TUMOR DNA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 46 ASIA PACIFIC: MARKET FOR CIRCULATING TUMOR DNA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 47 LATIN AMERICA: MARKET FOR CIRCULATING TUMOR DNA, BY COUNTRY, 2022-2029 (USD MILLION)
7.4 CELL-FREE DNA
7.4.1 GROWING APPLICATION OF CFDNA IN PRENATAL SCREENING TO DRIVE GROWTH
TABLE 48 MARKET FOR CELL-FREE DNA, BY REGION, 2022-2029 (USD MILLION)
TABLE 49 NORTH AMERICA: MARKET FOR CELL-FREE DNA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 50 EUROPE: MARKET FOR CELL-FREE DNA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 51 ASIA PACIFIC: MARKET FOR CELL-FREE DNA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 52 LATIN AMERICA: MARKET FOR CELL-FREE DNA, BY COUNTRY, 2022-2029 (USD MILLION)
7.5 EXTRACELLULAR VESICLES
7.5.1 HIGH STABILITY IN BLOOD CIRCULATION TO ENSURE CONSISTENT GROWTH
TABLE 53 MARKET FOR EXTRACELLULAR VESICLES, BY REGION, 2022-2029 (USD MILLION)
TABLE 54 NORTH AMERICA: MARKET FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 55 EUROPE: MARKET FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 56 ASIA PACIFIC: MARKET FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 57 LATIN AMERICA: MARKET FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2022-2029 (USD MILLION)
7.6 OTHER CIRCULATING BIOMARKERS
TABLE 58 MARKET FOR OTHER CIRCULATING BIOMARKERS, BY REGION, 2022-2029 (USD MILLION)
TABLE 59 NORTH AMERICA: MARKET FOR OTHER CIRCULATING BIOMARKERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 60 EUROPE: MARKET FOR OTHER CIRCULATING BIOMARKERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 61 ASIA PACIFIC: MARKET FOR OTHER CIRCULATING BIOMARKERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 62 LATIN AMERICA: MARKET FOR OTHER CIRCULATING BIOMARKERS, BY COUNTRY, 2022-2029 (USD MILLION)

8 LIQUID BIOPSY MARKET, BY TECHNOLOGY (Page No. - 126)
8.1 INTRODUCTION
TABLE 63 LIQUID BIOPSY INDUSTRY, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 64 NUMBER OF LIQUID BIOPSY SAMPLES TESTED GLOBALLY, BY TECHNOLOGY, 2022-2029 (MILLIONS)
8.1.1 KEY INDUSTRY INSIGHTS
8.2 MULTI-GENE PARALLEL ANALYSIS USING NGS
8.2.1 HIGH SENSITIVITY COUPLED WITH HIGHER THROUGHPUT EFFICIENCY TO DRIVE GROWTH
TABLE 65 MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY REGION, 2022-2029 (USD MILLION)
TABLE 66 NORTH AMERICA: MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 67 EUROPE: MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 68 ASIA PACIFIC: MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 69 LATIN AMERICA: MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY COUNTRY, 2022-2029 (USD MILLION)
8.3 SINGLE-GENE ANALYSIS USING PCR
8.3.1 COST BENEFITS OF PCR TECHNOLOGY TO DRIVE ADOPTION
TABLE 70 MARKET FOR SINGLE-GENE ANALYSIS USING PCR, BY REGION, 2022-2029 (USD MILLION)
TABLE 71 NORTH AMERICA: MARKET FOR SINGLE-GENE ANALYSIS USING PCR, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 72 EUROPE: MARKET FOR SINGLE-GENE ANALYSIS USING PCR, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 73 ASIA PACIFIC: MARKET FOR SINGLE-GENE ANALYSIS USING PCR, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 74 LATIN AMERICA: MARKET FOR SINGLE-GENE ANALYSIS USING PCR, BY COUNTRY, 2022-2029 (USD MILLION)

9 LIQUID BIOPSY MARKET, BY APPLICATION (Page No. - 133)
9.1 INTRODUCTION
TABLE 75 LIQUID BIOPSY INDUSTRY, BY APPLICATION, 2022-2029 (USD MILLION)
9.2 CANCER APPLICATIONS
TABLE 76 GLOBAL CANCER INCIDENCE, 2022 VS. 2045, BY REGION
TABLE 77 MARKET FOR CANCER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
TABLE 78 NORTH AMERICA: MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 79 EUROPE: MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 80 ASIA PACIFIC: MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 81 LATIN AMERICA: MARKET FOR CANCER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 82 MARKET FOR CANCER APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
9.2.1 LUNG CANCER
9.2.1.1 Growing prevalence of lung cancer to propel market growth
TABLE 83 GLOBAL LUNG CANCER INCIDENCE, 2022 VS. 2045
TABLE 84 MARKET FOR LUNG CANCER, BY REGION, 2022-2029 (USD MILLION)
TABLE 85 NORTH AMERICA: MARKET FOR LUNG CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 86 EUROPE: MARKET FOR LUNG CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 87 ASIA PACIFIC: MARKET FOR LUNG CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 88 LATIN AMERICA: MARKET FOR LUNG CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
9.2.2 BREAST CANCER
9.2.2.1 Increasing funding for breast cancer research to spur growth
TABLE 89 GLOBAL BREAST CANCER INCIDENCE, 2022 VS. 2045
TABLE 90 MARKET FOR BREAST CANCER, BY REGION, 2022-2029 (USD MILLION)
TABLE 91 NORTH AMERICA: MARKET FOR BREAST CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 92 EUROPE: MARKET FOR BREAST CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 93 ASIA PACIFIC: MARKET FOR BREAST CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 94 LATIN AMERICA: MARKET FOR BREAST CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
9.2.3 COLORECTAL CANCER
9.2.3.1 Rising prevalence of colorectal cancer to propel market
TABLE 95 GLOBAL COLORECTAL CANCER INCIDENCE, 2022 VS. 2045
TABLE 96 MARKET FOR COLORECTAL CANCER, BY REGION, 2022-2029 (USD MILLION)
TABLE 97 NORTH AMERICA: MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 98 EUROPE: MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 99 ASIA PACIFIC: MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 100 LATIN AMERICA: MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
9.2.4 PROSTATE CANCER
9.2.4.1 Rising patient population to support market growth
TABLE 101 GLOBAL PROSTATE CANCER INCIDENCE, 2022 VS. 2045
TABLE 102 MARKET FOR PROSTATE CANCER, BY REGION, 2022-2029 (USD MILLION)
TABLE 103 NORTH AMERICA: MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 104 EUROPE: MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 105 ASIA PACIFIC: MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 106 LATIN AMERICA: MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
9.2.5 MELANOMA
9.2.5.1 Growing need for early diagnosis of genetically mutated tumors to drive market
TABLE 107 GLOBAL MELANOMA INCIDENCE, 2022 VS. 2045
TABLE 108 MARKET FOR MELANOMA, BY REGION, 2022-2029 (USD MILLION)
TABLE 109 NORTH AMERICA: MARKET FOR MELANOMA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 110 EUROPE: MARKET FOR MELANOMA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 111 ASIA PACIFIC: MARKET FOR MELANOMA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 112 LATIN AMERICA: MARKET FOR MELANOMA, BY COUNTRY, 2022-2029 (USD MILLION)
9.2.6 OTHER CANCERS
TABLE 113 GLOBAL INCIDENCE OF OTHER CANCERS, 2022
TABLE 114 MARKET FOR OTHER CANCERS, BY REGION, 2022-2029 (USD MILLION)
TABLE 115 NORTH AMERICA: MARKET FOR OTHER CANCERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 116 EUROPE: MARKET FOR OTHER CANCERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 117 ASIA PACIFIC: MARKET FOR OTHER CANCERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 118 LATIN AMERICA: MARKET FOR OTHER CANCERS, BY COUNTRY, 2022-2029 (USD MILLION)
9.3 NON-CANCER APPLICATIONS
TABLE 119 MARKET FOR NON-CANCER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
TABLE 120 NORTH AMERICA: MARKET FOR NON-CANCER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 121 EUROPE: MARKET FOR NON-CANCER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 122 ASIA PACIFIC: MARKET FOR NON-CANCER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 123 LATIN AMERICA: MARKET FOR NON-CANCER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 124 MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
9.3.1 NON-INVASIVE PRENATAL TESTING
9.3.1.1 Growing demand for NIPT in high-risk pregnancies to drive market
TABLE 125 MARKET FOR NIPT, BY REGION, 2022-2029 (USD MILLION)
TABLE 126 NORTH AMERICA: MARKET FOR NIPT, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 127 EUROPE: MARKET FOR NIPT, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 128 ASIA PACIFIC: MARKET FOR NIPT, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 129 LATIN AMERICA: MARKET FOR NIPT, BY COUNTRY, 2022-2029 (USD MILLION)
9.3.2 ORGAN TRANSPLANTATION
9.3.2.1 Need for early detection of rejection to improve survival chances to drive growth
TABLE 130 MARKET FOR ORGAN TRANSPLANTATION, BY REGION, 2022-2029 (USD MILLION)
TABLE 131 NORTH AMERICA: MARKET FOR ORGAN TRANSPLANTATION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 132 EUROPE: MARKET FOR ORGAN TRANSPLANTATION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 133 ASIA PACIFIC: MARKET FOR ORGAN TRANSPLANTATION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 134 LATIN AMERICA: MARKET FOR ORGAN TRANSPLANTATION, BY COUNTRY, 2022-2029 (USD MILLION)
9.3.3 INFECTIOUS DISEASE TESTING
9.3.3.1 Potential accuracy and efficacy to support development of novel tests
TABLE 135 MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 2022-2029 (USD MILLION)
TABLE 136 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 137 EUROPE: MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 138 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 139 LATIN AMERICA: MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2022-2029 (USD MILLION)

10 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION (Page No. - 163)
10.1 INTRODUCTION
TABLE 140 LIQUID BIOPSY INDUSTRY, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
10.2 THERAPY SELECTION
10.2.1 THERAPY SELECTION TO HOLD LARGEST SHARE
TABLE 141 MARKET FOR THERAPY SELECTION, BY REGION, 2022-2029 (USD MILLION)
TABLE 142 NORTH AMERICA: MARKET FOR THERAPY SELECTION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 143 EUROPE: MARKET FOR THERAPY SELECTION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 144 ASIA PACIFIC: MARKET FOR THERAPY SELECTION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 145 LATIN AMERICA: MARKET FOR THERAPY SELECTION, BY COUNTRY, 2022-2029 (USD MILLION)
10.3 TREATMENT MONITORING
10.3.1 EARLY DETECTION OF ALTERATIONS ASSOCIATED WITH DRUG RESISTANCE TO DRIVE ADOPTION
TABLE 146 MARKET FOR TREATMENT MONITORING, BY REGION, 2022-2029 (USD MILLION)
TABLE 147 NORTH AMERICA: MARKET FOR TREATMENT MONITORING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 148 EUROPE: MARKET FOR TREATMENT MONITORING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 149 ASIA PACIFIC: MARKET FOR TREATMENT MONITORING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 150 LATIN AMERICA: MARKET FOR TREATMENT MONITORING, BY COUNTRY, 2022-2029 (USD MILLION)
10.4 EARLY CANCER SCREENING
10.4.1 POTENTIAL FOR EARLY CANCER DETECTION TO DRIVE MARKET
TABLE 151 MARKET FOR EARLY CANCER SCREENING, BY REGION, 2022-2029 (USD MILLION)
TABLE 152 NORTH AMERICA: MARKET FOR EARLY CANCER SCREENING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 153 EUROPE: MARKET FOR EARLY CANCER SCREENING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 154 ASIA PACIFIC: MARKET FOR EARLY CANCER SCREENING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 155 LATIN AMERICA: MARKET FOR EARLY CANCER SCREENING, BY COUNTRY, 2022-2029 (USD MILLION)
10.5 RECURRENCE MONITORING
10.5.1 NEED FOR POST-TREATMENT SURVEILLANCE TO DRIVE DEMAND
TABLE 156 MARKET FOR RECURRENCE MONITORING, BY REGION, 2022-2029 (USD MILLION)
TABLE 157 NORTH AMERICA: MARKET FOR RECURRENCE MONITORING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 158 EUROPE: MARKET FOR RECURRENCE MONITORING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 159 ASIA PACIFIC: MARKET FOR RECURRENCE MONITORING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 160 LATIN AMERICA: MARKET FOR RECURRENCE MONITORING, BY COUNTRY, 2022-2029 (USD MILLION)

11 LIQUID BIOPSY MARKET, BY SAMPLE TYPE (Page No. - 174)
11.1 INTRODUCTION
TABLE 161 LIQUID BIOPSY INDUSTRY, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
TABLE 162 LIQUID BIOPSY SAMPLES AND APPLICATIONS
11.1.1 KEY INDUSTRY INSIGHTS
11.2 BLOOD SAMPLES
11.2.1 SIMPLICITY, NON-INVASIVENESS TO DRIVE UPTAKE
TABLE 163 MARKET FOR BLOOD SAMPLES, BY REGION, 2022-2029 (USD MILLION)
TABLE 164 NORTH AMERICA: MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 165 EUROPE: MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 166 ASIA PACIFIC: MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 167 LATIN AMERICA: MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
11.3 OTHER SAMPLE TYPES
TABLE 168 MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2022-2029 (USD MILLION)
TABLE 169 NORTH AMERICA: MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 170 EUROPE: MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 171 ASIA PACIFIC: MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 172 LATIN AMERICA: MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)

12 LIQUID BIOPSY MARKET, BY END USER (Page No. - 182)
12.1 INTRODUCTION
TABLE 173 LIQUID BIOPSY INDUSTRY, BY END USER, 2022-2029 (USD MILLION)
12.2 REFERENCE LABORATORIES
12.2.1 INCREASING OUTSOURCING OF LIQUID BIOPSY TESTS TO DRIVE MARKET
TABLE 174 MARKET FOR REFERENCE LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
TABLE 175 NORTH AMERICA: MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 176 EUROPE: MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 177 ASIA PACIFIC: MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 178 LATIN AMERICA: MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
12.3 HOSPITALS & PHYSICIAN LABORATORIES
12.3.1 GROWING NUMBER OF HOSPITALS WORLDWIDE TO BOOST GROWTH
TABLE 179 MARKET FOR HOSPITALS & PHYSICIAN LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
TABLE 180 NORTH AMERICA: MARKET FOR HOSPITALS & PHYSICIAN LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 181 EUROPE: MARKET FOR HOSPITALS & PHYSICIAN LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 182 ASIA PACIFIC: MARKET FOR HOSPITALS & PHYSICIAN LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 183 LATIN AMERICA: MARKET FOR HOSPITALS & PHYSICIAN LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
12.4 ACADEMIC & RESEARCH CENTERS
12.4.1 GROWING FOCUS ON R&D INTO INNOVATIVE LIQUID BIOPSY TESTS TO FUEL GROWTH
TABLE 184 MARKET FOR ACADEMIC & RESEARCH CENTERS, BY REGION, 2022-2029 (USD MILLION)
TABLE 185 NORTH AMERICA: MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 186 EUROPE: MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 187 ASIA PACIFIC: MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 188 LATIN AMERICA: MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
12.5 OTHER END USERS
TABLE 189 MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
TABLE 190 NORTH AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 191 EUROPE: MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 192 ASIA PACIFIC: MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 193 LATIN AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)

13 LIQUID BIOPSY MARKET, BY REGION (Page No. - 193)
13.1 INTRODUCTION
TABLE 194 LIQUID BIOPSY INDUSTRY, BY REGION, 2022-2029 (USD MILLION)
13.2 NORTH AMERICA
TABLE 195 NORTH AMERICA: NUMBER OF NEW CANCER CASES, BY CANCER TYPE, 2022
13.2.1 NORTH AMERICA: RECESSION IMPACT
FIGURE 34 NORTH AMERICA: LIQUID BIOPSY MARKET SNAPSHOT
TABLE 196 NORTH AMERICA: MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 197 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 198 NORTH AMERICA: MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
TABLE 199 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 200 NORTH AMERICA: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 201 NORTH AMERICA: MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
TABLE 202 NORTH AMERICA: MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
TABLE 203 NORTH AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
13.2.2 US
13.2.2.1 Increasing prevalence of cancer to drive growth
TABLE 204 US: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 205 US: MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
TABLE 206 US: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 207 US: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 208 US: MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
TABLE 209 US: MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
TABLE 210 US: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
13.2.3 CANADA
13.2.3.1 Availability of various cancer screening programs to drive growth
TABLE 211 CANADA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 212 CANADA: MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
TABLE 213 CANADA: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 214 CANADA: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 215 CANADA: MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
TABLE 216 CANADA: MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
TABLE 217 CANADA: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
13.3 EUROPE
13.3.1 EUROPE: RECESSION IMPACT
TABLE 218 EUROPE: LIQUID BIOPSY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 219 EUROPE: MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 220 EUROPE: MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
TABLE 221 EUROPE: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 222 EUROPE: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 223 EUROPE: MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
TABLE 224 EUROPE: MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
TABLE 225 EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
13.3.2 GERMANY
13.3.2.1 Favorable government health policies to support market growth
TABLE 226 GERMANY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 227 GERMANY: MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
TABLE 228 GERMANY: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 229 GERMANY: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 230 GERMANY: MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
TABLE 231 GERMANY: MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
TABLE 232 GERMANY: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
13.3.3 UK
13.3.3.1 Rising government healthcare expenditure to propel market growth
TABLE 233 UK: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 234 UK: MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
TABLE 235 UK: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 236 UK: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 237 UK: MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
TABLE 238 UK: MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
TABLE 239 UK: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
13.3.4 FRANCE
13.3.4.1 Rising R&D expenditure to drive market growth
TABLE 240 FRANCE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 241 FRANCE: MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
TABLE 242 FRANCE: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 243 FRANCE: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 244 FRANCE: MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
TABLE 245 FRANCE: MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
TABLE 246 FRANCE: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
13.3.5 ITALY
13.3.5.1 Growing research into novel circulating cancer biomarkers to drive market growth
TABLE 247 ITALY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 248 ITALY: MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
TABLE 249 ITALY: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 250 ITALY: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 251 ITALY: MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
TABLE 252 ITALY: MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
TABLE 253 ITALY: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
13.3.6 SPAIN
13.3.6.1 Focus on personalized medicine to support market growth
TABLE 254 SPAIN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 255 SPAIN: MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
TABLE 256 SPAIN: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 257 SPAIN: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 258 SPAIN: MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
TABLE 259 SPAIN: MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
TABLE 260 SPAIN: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
13.3.7 REST OF EUROPE
TABLE 261 REST OF EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 262 REST OF EUROPE: MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
TABLE 263 REST OF EUROPE: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 264 REST OF EUROPE: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 265 REST OF EUROPE: MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
TABLE 266 REST OF EUROPE: MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
TABLE 267 REST OF EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
13.4 ASIA PACIFIC
13.4.1 ASIA PACIFIC: RECESSION IMPACT
FIGURE 35 ASIA PACIFIC: LIQUID BIOPSY MARKET SNAPSHOT
TABLE 268 ASIA PACIFIC: MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 269 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 270 ASIA PACIFIC: MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
TABLE 271 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 272 ASIA PACIFIC: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 273 ASIA PACIFIC: MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
TABLE 274 ASIA PACIFIC: MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
TABLE 275 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
13.4.2 CHINA
13.4.2.1 Growing public access to advanced healthcare facilities to drive market
TABLE 276 CHINA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 277 CHINA: MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
TABLE 278 CHINA: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 279 CHINA: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 280 CHINA: MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
TABLE 281 CHINA: MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
TABLE 282 CHINA: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
13.4.3 JAPAN
13.4.3.1 Universal healthcare reimbursement policy to fuel growth
TABLE 283 JAPAN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 284 JAPAN: MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
TABLE 285 JAPAN: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 286 JAPAN: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 287 JAPAN: MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
TABLE 288 JAPAN: MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
TABLE 289 JAPAN: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
13.4.4 INDIA
13.4.4.1 Increasing investments in healthcare systems to drive adoption of liquid biopsy products
TABLE 290 INDIA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 291 INDIA: MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
TABLE 292 INDIA: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 293 INDIA: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 294 INDIA: MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
TABLE 295 INDIA: MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
TABLE 296 INDIA: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
13.4.5 REST OF ASIA PACIFIC
TABLE 297 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 298 REST OF ASIA PACIFIC: MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
TABLE 299 REST OF ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 300 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 301 REST OF ASIA PACIFIC: MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
TABLE 302 REST OF ASIA PACIFIC: MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
TABLE 303 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
13.5 LATIN AMERICA
13.5.1 INCREASING PRIVATE & PUBLIC INVESTMENTS TO DRIVE MARKET
13.5.2 LATIN AMERICA: RECESSION IMPACT
TABLE 304 LATIN AMERICA: LIQUID BIOPSY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 305 LATIN AMERICA: MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 306 LATIN AMERICA: MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
TABLE 307 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 308 LATIN AMERICA: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 309 LATIN AMERICA: MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
TABLE 310 LATIN AMERICA: MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
TABLE 311 LATIN AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
13.5.3 BRAZIL
13.5.3.1 Improving healthcare infrastructure and supportive regulatory environment to fuel market
TABLE 312 BRAZIL: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 313 BRAZIL: MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
TABLE 314 BRAZIL: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 315 BRAZIL: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 316 BRAZIL: MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
TABLE 317 BRAZIL: MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
TABLE 318 BRAZIL: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
13.5.4 MEXICO
13.5.4.1 Improving accessibility and affordability of healthcare services to support market growth
TABLE 319 MEXICO: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 320 MEXICO: MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
TABLE 321 MEXICO: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 322 MEXICO: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 323 MEXICO: MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
TABLE 324 MEXICO: MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
TABLE 325 MEXICO: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
13.5.5 REST OF LATIN AMERICA
TABLE 326 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 327 REST OF LATIN AMERICA: MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
TABLE 328 REST OF LATIN AMERICA: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 329 REST OF LATIN AMERICA: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 330 REST OF LATIN AMERICA: MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
TABLE 331 REST OF LATIN AMERICA: MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
TABLE 332 REST OF LATIN AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
13.6 MIDDLE EAST & AFRICA
13.6.1 INCREASED FUNDING IN RESEARCH TO DRIVE MARKET
13.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
TABLE 333 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 334 MIDDLE EAST & AFRICA: MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
TABLE 335 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 336 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 337 MIDDLE EAST & AFRICA: MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
TABLE 338 MIDDLE EAST & AFRICA: MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
TABLE 339 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
13.7 GCC COUNTRIES
13.7.1 RISING FOCUS ON ADVANCED HEALTH INFRASTRUCTURE TO DRIVE MARKET GROWTH
13.7.2 GCC COUNTRIES: RECESSION IMPACT
TABLE 340 GCC COUNTRIES: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 341 GCC COUNTRIES: MARKET, BY CIRCULATING BIOMARKER, 2022-2029 (USD MILLION)
TABLE 342 GCC COUNTRIES: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 343 GCC COUNTRIES: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 344 GCC COUNTRIES: MARKET, BY CLINICAL APPLICATION, 2022-2029 (USD MILLION)
TABLE 345 GCC COUNTRIES: MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
TABLE 346 GCC COUNTRIES: LIQUID BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)

14 COMPETITIVE LANDSCAPE (Page No. - 262)
14.1 INTRODUCTION
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
14.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN LIQUID BIOPSY MARKET
14.3 REVENUE ANALYSIS
FIGURE 36 TOP FIVE PLAYERS HAVE DOMINATED LIQUID BIOPSY INDUSTRY IN LAST FIVE YEARS
14.4 MARKET SHARE ANALYSIS
14.4.1 LIQUID BIOPSY INDUSTRY
FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
TABLE 347 LIQUID BIOPSY INDUSTRY: DEGREE OF COMPETITION
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
14.5.1 STARS
14.5.2 EMERGING LEADERS
14.5.3 PERVASIVE PLAYERS
14.5.4 PARTICIPANTS
FIGURE 38 LIQUID BIOPSY INDUSTRY: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
14.5.5 COMPANY FOOTPRINT
FIGURE 39 LIQUID BIOPSY INDUSTRY: COMPANY FOOTPRINT
TABLE 348 LIQUID BIOPSY INDUSTRY: PRODUCT & SERVICE FOOTPRINT
TABLE 349 LIQUID BIOPSY INDUSTRY: REGIONAL FOOTPRINT
TABLE 350 LIQUID BIOPSY INDUSTRY: APPLICATION FOOTPRINT
14.6 COMPANY EVALUATION MATRIX: START-UPS/SMES
14.6.1 PROGRESSIVE COMPANIES
14.6.2 RESPONSIVE COMPANIES
14.6.3 DYNAMIC COMPANIES
14.6.4 STARTING BLOCKS
FIGURE 40 LIQUID BIOPSY INDUSTRY: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023
14.6.5 COMPETITIVE BENCHMARKING
TABLE 351 LIQUID BIOPSY INDUSTRY: DETAILED LIST OF KEY START-UPS/SMES
TABLE 352 LIQUID BIOPSY INDUSTRY: COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES
14.7 VALUATION AND FINANCIAL METRICS OF LIQUID BIOPSY VENDORS
FIGURE 41 EV/EBITDA OF KEY VENDORS
FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
14.8 BRAND/PRODUCT COMPARISON
FIGURE 43 BRAND COMPARISON: PCR-BASED LIQUID BIOPSY ASSAYS
14.8.1 QIAGEN
14.8.2 THERMO FISHER SCIENTIFIC INC.
14.8.3 BIO-RAD LABORATORIES, INC.
14.9 COMPETITIVE SCENARIO
14.9.1 PRODUCT LAUNCHES
TABLE 353 LIQUID BIOPSY INDUSTRY: PRODUCT LAUNCHES, JANUARY 2021-APRIL 2024
14.9.2 DEALS
TABLE 354 LIQUID BIOPSY INDUSTRY: DEALS, JANUARY 2021-APRIL 2024
14.9.3 EXPANSIONS
TABLE 355 LIQUID BIOPSY MARKET: EXPANSIONS, JANUARY 2021-APRIL 2024

15 COMPANY PROFILES (Page No. - 277)
15.1 KEY PLAYERS
(Business overview, Products offered, Recent developments, MnM view, Key strategies, Strategic choices made, and Weaknesses and Competitive threats)*
15.1.1 NATERA, INC.
TABLE 356 NATERA, INC.: COMPANY OVERVIEW
FIGURE 44 NATERA, INC.: COMPANY SNAPSHOT (2023)
TABLE 357 NATERA, INC.: PRODUCTS OFFERED
TABLE 358 NATERA, INC.: DEALS
15.1.2 QIAGEN
TABLE 359 QIAGEN: COMPANY OVERVIEW
FIGURE 45 QIAGEN: COMPANY SNAPSHOT (2023)
TABLE 360 QIAGEN: PRODUCTS OFFERED
TABLE 361 QIAGEN: PRODUCT LAUNCHES & APPROVALS
TABLE 362 QIAGEN: DEALS
TABLE 363 QIAGEN: EXPANSIONS
15.1.3 MYRIAD GENETICS, INC.
TABLE 364 MYRIAD GENETICS, INC.: COMPANY OVERVIEW
FIGURE 46 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2023)
TABLE 365 MYRIAD GENETICS, INC.: PRODUCTS OFFERED
TABLE 366 MYRIAD GENETICS, INC.: PRODUCT LAUNCHES
TABLE 367 MYRIAD GENETICS, INC.: DEALS
15.1.4 ILLUMINA, INC.
TABLE 368 ILLUMINA, INC.: COMPANY OVERVIEW
FIGURE 47 ILLUMINA, INC.: COMPANY SNAPSHOT (2023)
TABLE 369 ILLUMINA, INC.: PRODUCTS OFFERED
TABLE 370 ILLUMINA, INC.: PRODUCT LAUNCHES
TABLE 371 ILLUMINA, INC.: DEALS
TABLE 372 ILLUMINA, INC.: EXPANSIONS
15.1.5 F. HOFFMANN-LA ROCHE LTD.
TABLE 373 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
FIGURE 48 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
TABLE 374 F. HOFFMAN-LA ROCHE LTD.: PRODUCTS OFFERED
TABLE 375 F. HOFFMAN-LA ROCHE LTD.: PRODUCT LAUNCHES
15.1.6 THERMO FISHER SCIENTIFIC INC.
TABLE 376 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
FIGURE 49 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
TABLE 377 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
TABLE 378 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES
TABLE 379 THERMO FISHER SCIENTIFIC INC.: DEALS
TABLE 380 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS
15.1.7 GUARDANT HEALTH
TABLE 381 GUARDANT HEALTH: COMPANY OVERVIEW
FIGURE 50 GUARDANT HEALTH: COMPANY SNAPSHOT (2023)
TABLE 382 GUARDANT HEALTH: PRODUCTS OFFERED
TABLE 383 GUARDANT HEALTH: PRODUCT LAUNCHES & APPROVALS
TABLE 384 GUARDANT HEALTH: DEALS
15.1.8 BIO-RAD LABORATORIES, INC.
TABLE 385 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
FIGURE 51 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)
TABLE 386 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
TABLE 387 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES
TABLE 388 BIO-RAD LABORATORIES, INC.: DEALS
15.1.9 EXACT SCIENCES CORPORATION
TABLE 389 EXACT SCIENCES CORPORATION: COMPANY OVERVIEW
FIGURE 52 EXACT SCIENCES CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 390 EXACT SCIENCES CORPORATION: PRODUCTS OFFERED
TABLE 391 EXACT SCIENCES CORPORATION: DEALS
15.1.10 SYSMEX CORPORATION
TABLE 392 SYSMEX CORPORATION: COMPANY OVERVIEW
FIGURE 53 SYSMEX CORPORATION: COMPANY SNAPSHOT (2022)
TABLE 393 SYSMEX CORPORATION: PRODUCTS OFFERED
TABLE 394 SYSMEX CORPORATION: DEALS
TABLE 395 SYSMEX CORPORATION: EXPANSIONS
15.1.11 BIOCEPT, INC.
TABLE 396 BIOCEPT, INC.: COMPANY OVERVIEW
FIGURE 54 BIOCEPT, INC.: COMPANY SNAPSHOT (2022)
TABLE 397 BIOCEPT, INC.: PRODUCTS OFFERED
TABLE 398 BIOCEPT, INC.: PRODUCT LAUNCHES
TABLE 399 BIOCEPT, INC.: DEALS
15.1.12 MDXHEALTH
TABLE 400 MDXHEALTH: COMPANY OVERVIEW
FIGURE 55 MDXHEALTH: COMPANY SNAPSHOT (2022)
TABLE 401 MDXHEALTH: PRODUCTS OFFERED
TABLE 402 MDXHEALTH: DEALS
15.1.13 PERSONALIS, INC.
TABLE 403 PERSONALIS, INC.: COMPANY OVERVIEW
FIGURE 56 PERSONALIS, INC.: COMPANY SNAPSHOT (2023)
TABLE 404 PERSONALIS, INC.: PRODUCTS OFFERED
TABLE 405 PERSONALIS, INC.: PRODUCT LAUNCHES
TABLE 406 PERSONALIS, INC.: DEALS
15.2 OTHER PLAYERS
15.2.1 NEOGENOMICS LABORATORIES
15.2.2 EPIGENOMICS AG
15.2.3 ANGLE PLC
15.2.4 MENARINI-SILICON BIOSYSTEMS
15.2.5 LUNGLIFE AI, INC.
15.2.6 VORTEX BIOSCIENCES
15.2.7 BIO-TECHNE
15.2.8 MESA LABS, INC.
15.2.9 LABORATORY CORPORATION OF AMERICA HOLDINGS
15.2.10 MEDGENOME
15.2.11 STRAND
15.2.12 FREENOME HOLDINGS, INC.
15.2.13 LUCENCE HEALTH INC.
*Details on Business overview, Products offered, Recent developments, MnM view, Key strategies, Strategic choices made, and Weaknesses and Competitive threats might not be captured in case of unlisted companies.

16 APPENDIX (Page No. - 335)
16.1 DISCUSSION GUIDE
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
16.3 CUSTOMIZATION OPTIONS
16.4 RELATED REPORTS
16.5 AUTHOR DETAILS